Keith Flaherty is listed as a director on 3 SEC Form D filings by 1 issuer between May 2018 and Nov 2024: Strata Oncology, Inc. (Ann Arbor, MI — industry reported as "Other" — 2018–2024; $11.8M reported sold to 14 investors).
What this means One deal on file with the SEC. A Form D is the notice a company files after it starts selling a private investment — it is a notice, not an approval.
Listed alongside Daniel Rhodes (3 shared filings), Jan Garfinkle (3 shared filings), Jeffrey Williams (3 shared filings), Matthew Martin (3 shared filings), Nicole Walker (2 shared filings) and 5 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Keith. Each name links to their own page.
The issuer belongs to the sponsor group Tangent (2 issuers, $7.15M reported sold, 2011–2024).
What this means A sponsor group is one team that sets up a new company for each deal. Tangent has 2 companies on file and $7.15M reported sold in total — the group page shows the whole track record in one place.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — 1 bankruptcy case matching the name listed in Key records below.
What this means 1 record came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.
We compared 3 public filings for Keith Flaherty and found 7 differences: No amendment in the last 12 months on an offering that may still be open; Same name, different state: "Keith Flaherty" (MA) is a separate record; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.